BR112023024571A2 - Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos - Google Patents

Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos

Info

Publication number
BR112023024571A2
BR112023024571A2 BR112023024571A BR112023024571A BR112023024571A2 BR 112023024571 A2 BR112023024571 A2 BR 112023024571A2 BR 112023024571 A BR112023024571 A BR 112023024571A BR 112023024571 A BR112023024571 A BR 112023024571A BR 112023024571 A2 BR112023024571 A2 BR 112023024571A2
Authority
BR
Brazil
Prior art keywords
chk1
inhibitors
checkpoint kinase
methods
checkpoint
Prior art date
Application number
BR112023024571A
Other languages
English (en)
Portuguese (pt)
Inventor
b pinkerton Anthony
Jacques Mauger
Janette Elsdon Rachelle
Todd Meyer Stephen
Pham Hong Truong Yen
Original Assignee
Boundless Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boundless Bio Inc filed Critical Boundless Bio Inc
Publication of BR112023024571A2 publication Critical patent/BR112023024571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023024571A 2021-05-27 2022-05-26 Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos BR112023024571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163193990P 2021-05-27 2021-05-27
PCT/US2022/031141 WO2022251502A1 (en) 2021-05-27 2022-05-26 Checkpoint kinase 1 (chk1) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112023024571A2 true BR112023024571A2 (pt) 2024-02-06

Family

ID=84229213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024571A BR112023024571A2 (pt) 2021-05-27 2022-05-26 Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos

Country Status (12)

Country Link
US (2) US11707462B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347582A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520481A (cg-RX-API-DMAC7.html)
KR (1) KR20240021188A (cg-RX-API-DMAC7.html)
CN (1) CN117715905A (cg-RX-API-DMAC7.html)
AU (1) AU2022282384A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024571A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219348A1 (cg-RX-API-DMAC7.html)
IL (1) IL308759A (cg-RX-API-DMAC7.html)
MX (1) MX2023014028A (cg-RX-API-DMAC7.html)
TW (1) TW202313588A (cg-RX-API-DMAC7.html)
WO (1) WO2022251502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
MX2023006364A (es) * 2020-11-30 2023-06-13 Sumitomo Pharma Co Ltd Derivado de 5-heteroaril-1h-pirazol-3-amina.
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
CA3241992A1 (en) * 2021-12-24 2023-06-29 Seiji Kamioka 1h-pyrazole-3-amine derivative having bicyclic backbone
CN119546588A (zh) * 2022-05-24 2025-02-28 无界生物公司 吡啶检查点激酶1(chk1)抑制剂及其用途
CN119255990A (zh) * 2022-05-25 2025-01-03 曙方医药 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途
EP4626433A1 (en) * 2022-11-29 2025-10-08 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
TW202440549A (zh) * 2022-11-29 2024-10-16 美商無界生物公司 檢查點激酶1(chk1)抑制劑及其用途
EP4683635A1 (en) * 2023-03-20 2026-01-28 Boundless Bio, Inc. Uses of a checkpoint kinase 1 (chk1) inhibitor
JP2026513823A (ja) * 2023-04-03 2026-05-01 バウンドレス バイオ,インク. チェックポイントキナーゼ1(chk1)阻害剤の結晶形態およびその使用
US20260232659A1 (en) * 2023-04-03 2026-08-13 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition
EP4753712A1 (en) * 2023-08-02 2026-06-10 Health Research, Inc. Sequential treatment method for p53-deficient cancer
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026108769A1 (en) 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof
WO2026108771A2 (en) 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
CN122031724A (zh) * 2026-04-17 2026-05-15 中国科学院杭州医学研究所 编码p16蛋白的mRNA在制备用于治疗胰腺癌的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US20050209297A1 (en) * 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
DZ3398A1 (fr) * 2000-08-31 2002-03-07 Pfizer Prod Inc Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
CA3013514C (en) * 2016-02-04 2021-11-23 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
KR20220042159A (ko) * 2019-08-01 2022-04-04 인테그랄 바이오사이언스 피브이티. 엘티디. 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도
CN112457306A (zh) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN111253370B (zh) 2020-03-24 2021-08-03 浙江大学 N-多取代吡啶-2-氨基嘧啶类衍生物及用途
EP4741018A3 (en) * 2020-06-19 2026-07-15 Anaxis Pharma Pty Ltd Sulphonamide compounds
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
WO2022087326A1 (en) 2020-10-23 2022-04-28 Celgene Corporation Heterocyclic compounds and their use for treatment of helminthic infections and diseases
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
MX2023006364A (es) * 2020-11-30 2023-06-13 Sumitomo Pharma Co Ltd Derivado de 5-heteroaril-1h-pirazol-3-amina.
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
CA3241992A1 (en) 2021-12-24 2023-06-29 Seiji Kamioka 1h-pyrazole-3-amine derivative having bicyclic backbone
CN119546588A (zh) 2022-05-24 2025-02-28 无界生物公司 吡啶检查点激酶1(chk1)抑制剂及其用途
CN119255990A (zh) 2022-05-25 2025-01-03 曙方医药 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途
JPWO2023229032A1 (cg-RX-API-DMAC7.html) 2022-05-27 2023-11-30
TW202440549A (zh) 2022-11-29 2024-10-16 美商無界生物公司 檢查點激酶1(chk1)抑制劑及其用途
EP4626433A1 (en) 2022-11-29 2025-10-08 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
EP4683635A1 (en) 2023-03-20 2026-01-28 Boundless Bio, Inc. Uses of a checkpoint kinase 1 (chk1) inhibitor
JP2026513823A (ja) 2023-04-03 2026-05-01 バウンドレス バイオ,インク. チェックポイントキナーゼ1(chk1)阻害剤の結晶形態およびその使用
US20260232659A1 (en) 2023-04-03 2026-08-13 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition

Also Published As

Publication number Publication date
EP4347582A1 (en) 2024-04-10
AU2022282384A1 (en) 2023-12-14
MX2023014028A (es) 2023-12-12
KR20240021188A (ko) 2024-02-16
US12527790B2 (en) 2026-01-20
TW202313588A (zh) 2023-04-01
EP4347582A4 (en) 2025-05-07
IL308759A (en) 2024-01-01
CN117715905A (zh) 2024-03-15
JP2024520481A (ja) 2024-05-24
US20230026313A1 (en) 2023-01-26
CA3219348A1 (en) 2022-12-01
US11707462B2 (en) 2023-07-25
WO2022251502A1 (en) 2022-12-01
US20230310423A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
MX2023014028A (es) Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.
MX2024014500A (es) Inhibidores piridinicos de la cinasa 1 de puntos de regulacion (chk1) y usos de estos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
JOP20230190A1 (ar) مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس
CO2026004964A2 (es) Moduladores de kras
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112016008593A8 (pt) composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
BRPI0511350A (pt) composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
NZ770260A (en) Substituted heterocyclic inhibitors of ptpn11
CR20190361A (es) Dendrímeros terapéuticos
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
BR112021019703A2 (pt) Compostos heterocíclicos e usos dos mesmos

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BOUNDLESS BIO, INC. (US)